Patent ID: 11953500
Assignee: HEBEI YANDA LUDAOPEI HOSPITAL
Field: Measurement (Instruments)
Classification: CPC G | IPC G

Claim 0:
1. A reagent combination for detecting B-cell tumor after targeted therapy by flow cytometry, comprising a first group of antibodies, a second group of antibodies, and a third group of antibodies, wherein each antibody is a fluorescently-labeled monoclonal antibody; wherein:
the first group of antibodies consists of: an anti-CD38 antibody labeled with FITC, an anti-CD10 antibody labeled with PE, an anti-CD34 antibody labeled with PerCP-Cy5.5, an anti-CD19 antibody labeled with PE-Cy7, an anti-CD24 antibody labeled with APC, an anti-CD20 antibody labeled with APC-Cy7, an anti-CD81 antibody labeled with BV421, and an anti-CD45 antibody labeled with V500; the first group of antibodies being contained in a first container;
the second group of antibodies consists of: an anti-CD38 antibody labeled with FITC, an anti-CD10 antibody labeled with PE, an anti-CD34 antibody labeled with PerCP-Cy5.5, an anti-CD19 antibody labeled with PE-Cy7, an anti-CD20 antibody labeled with APC-Cy7, an anti-CD72 antibody labeled with BV421, and an anti-CD45 antibody labeled with V500; the second group of antibodies being contained in a second container;
the third group of antibodies consists of: an anti-cytoplasmic CD79a antibody labeled with APC; the third group of antibodies being contained accommodated in a third container;
wherein the B-cell tumor is B-cell acute lymphoblastic leukemia or B-cell non-Hodgkin's lymphoma.